NCT03634969View on ClinicalTrials.gov

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Cardiac FailureMyocardial Failure
Interventions
DRUG

BMS-986224

Specified dose on specified days

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

55114

Prism Research, Saint Paul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY